| Literature DB >> 30863462 |
Márton Kovács1,2, Attila Makkos1,2, Dávid Pintér1,2, Annamária Juhász1,2, Gergely Darnai2,3,4, Kázmér Karádi5, József Janszky2,3, Norbert Kovács2,3.
Abstract
BACKGROUND: Impulse control disorders in Parkinson's disease (PD) represent emerging problems with potentially devastating consequences. The standard screening methods for impulse control disorders are clinically imperfect. Although it is rarely reported, many patients utilize the Internet to fulfill their compulsive behaviors because of its easy accessibility. We designed a study to test the hypothesis that an active screening for excessive Internet use and Internet addiction might improve the sensitivity of identification of impulse control disorders.Entities:
Mesh:
Year: 2019 PMID: 30863462 PMCID: PMC6378069 DOI: 10.1155/2019/4925015
Source DB: PubMed Journal: Behav Neurol ISSN: 0953-4180 Impact factor: 3.342
The demographic and disease-specific characteristics of the study population reporting regular Internet usage (n = 106).
| Mean/count | Standard deviation/percentage | Median | Percentile 25 | Percentile 75 | ||
|---|---|---|---|---|---|---|
| Age (years) | 71.0 | 0.0 | 70 | 65 | 75 | |
| Sex | Male | 64 | 60.4% | |||
| Female | 42 | 39.6% | ||||
| Education (years) | 12.5 | 3.4 | 12 | 11 | 16 | |
| Disease duration (years) | 10.0 | 3.6 | 10 | 3 | 13 | |
| Levodopa duration (years) | 6.3 | 4.4 | 5 | 3 | 9 | |
| Disease subtype | Tremor-dominant | 40 | 37.7% | |||
| Rigid-akinetic | 40 | 37.7% | ||||
| Mixed | 26 | 24.6% | ||||
| Disease severity | Mild (HYS 1 & 2) | 66 | 62.3% | |||
| Moderate (HYS 3) | 22 | 20.7% | ||||
| Severe (HYS 4 & 5) | 18 | 17.0% | ||||
| Levodopa usage | 60 | 56.6% | ||||
| Dopamine agonist usage | 65 | 61.3% | ||||
| Monoamine oxidase inhibitor usage | 18 | 16.9% | ||||
| Catechol-O-methyltransferase inhibitor usage | 23 | 21.7% | ||||
| Anticholinergic usage | 0 | 0% | ||||
| Deep brain stimulator usage | 20 | 18.9% | ||||
| LED | 384.2 | 509.8 | 300 | 0 | 600 | |
| Dopamine agonist LED | 108.2 | 170.6 | 40 | 0 | 160 | |
| Total LED | 628.7 | 1085.2 | 400 | 100 | 822 | |
| Lille Apathy Rating Scale | -24.0 | 6.8 | -26 | -28 | -21 | |
| Montgomery-Asberg Depression Rating Scale | 10.0 | 5.4 | 10 | 6 | 14 | |
| Montreal Cognitive Assessment | 24.2 | 3.4 | 25 | 22 | 28 | |
| Parkinson Anxiety Scale | 11.4 | 7.3 | 11 | 7 | 17 | |
| MDS-UPDRS nM-EDL | 11.5 | 6.5 | 11 | 7 | 15 | |
| MDS-UPDRS M-EDL | 12.1 | 8.0 | 12 | 5 | 18 | |
| MDS-UPDRS ME | 28.8 | 12.8 | 28 | 19 | 38 | |
| MDS-UPDRS MC | 2.9 | 2.7 | 2 | 0 | 4 | |
| MDS-UPDRS total score | 55.1 | 23.7 | 53 | 36 | 73 | |
| UDysRS part 1 | 8.1 | 8.6 | 6 | 0 | 15 | |
| UDysRS part 2 | 3.8 | 3.1 | 4 | 1 | 6 | |
| UDysRS part 3 | 7.2 | 3.8 | 5 | 0 | 3 | |
| UDysRS part 4 | 1.4 | 2.0 | 0 | 0 | 3 | |
| UDysRS total score | 20.5 | 13.3 | 16 | 5 | 22 | |
| PDQ-39 SI | 20.5 | 14.4 | 18.0 | 10.0 | 30.0 | |
HYS = Hoehn-Yahr stages; LED = Levodopa equivalent dosage; MDS-UPDRS = Movement Disorders Society sponsored version of Unified Parkinson's Disease Rating Scale; MDS-UPDRS MC = motor complications (part IV of MDS-UPDRS); MDS-UPDRS ME = motor examination (part III of MDS-UPDRS); MDS-UPDRS M-EDL = motor experiences of daily living (part II of MDS-UPDRS); MDS-UPDRS nM-EDL = nonmotor experiences of daily living (part I of MDS-UPDRS); PDQ-39 SI = 39-item Parkinson's Disease Questionnaire Summary Index; UDysRS = Unified Dyskinesia Rating Scale (measured only on patients having dyskinesia, n = 50).
Comparison between Parkinson's disease patients with and without impulse control disorders (PD-ICD and No ICDs, respectively).
| No ICDs | PD-ICD | Significance | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | Standard deviation | Median | Percentile 25 | Percentile 75 | Mean | Standard deviation | Median | Percentile 25 | Percentile 75 | ||
| PIUQ Obsession subscale | 6.2 | 0.2 | 6 | 6 | 6 | 10.2 | 2.4 | 9 | 6 | 10 |
|
| PIUQ Neglect subscale | 6.3 | 0.2 | 6 | 6 | 6 | 11.5 | 1.8 | 11 | 8 | 11 |
|
| PIUQ Control subscale | 6.3 | 0.2 | 6 | 6 | 6 | 10.5 | 2.2 | 10 | 6 | 10 |
|
| PIUQ total score | 19.2 | 0.4 | 18 | 18 | 18 | 32.2 | 5.4 | 31 | 22 | 29 |
|
| mMIDI total score | 0.8 | 5.4 | 0 | 0 | 1 | 4.4 | 7.1 | 0 | 0 | 6 |
|
| PDQ-39 SI | 19.5 | 13.9 | 18 | 8 | 28 | 23.2 | 15.7 | 19 | 13 | 32 | |
| MDS-UPDRS total score | 55.3 | 23.5 | 53 | 36 | 74 | 54.8 | 24.8 | 53 | 36 | 66 | |
| MDS-UPDRS nM-EDL | 10.7 | 5.9 | 10 | 6 | 15 | 13.6 | 7.6 | 14 | 7 | 19 |
|
| MDS-UPDRS M-EDL | 11.4 | 7.6 | 11 | 5 | 17 | 13.8 | 8.9 | 12 | 8 | 18 | |
| MDS-UPDRS ME | 30.1 | 13.1 | 30 | 20 | 38 | 25.2 | 11.5 | 22 | 19 | 37 | |
| MDS-UPDRS MC | 3.0 | 2.6 | 4 | 1 | 4 | 2.7 | 3.0 | 2 | 0 | 4 | |
| Lille Apathy Rating Scale | -23.7 | 7.1 | -26 | -28 | -20 | -24.8 | 5.9 | -26 | -28 | -23 | |
| Montgomery-Asberg Depression Rating Scale | 9.5 | 5.3 | 9 | 6 | 13 | 11.5 | 5.4 | 12 | 8 | 15 | |
| Parkinson Anxiety Scale | 11.2 | 7.2 | 10 | 7 | 15 | 12.0 | 7.6 | 11 | 7 | 17 | |
| LED | 404.1 | 545.5 | 300 | 0 | 600 | 331.5 | 403.8 | 200 | 0 | 585 | |
| Dopamine agonist LED | 79.3 | 132.2 | 0 | 0 | 154 | 185.1 | 230.8 | 150 | 0 | 300 |
|
| Total LED | 525.5 | 599.2 | 400 | 80 | 810 | 902.8 | 1826.0 | 550 | 154 | 900 | |
HYS = Hoehn-Yahr stages; LED = Levodopa equivalent dosage; MDS-UPDRS = Movement Disorders Society sponsored version of Unified Parkinson's Disease Rating Scale; MDS-UPDRS MC = motor complications (part IV of MDS-UPDRS); MDS-UPDRS ME = motor examination (part III of MDS-UPDRS); MDS-UPDRS M-EDL = motor experiences of daily living (part II of MDS-UPDRS); MDS-UPDRS nM-EDL = nonmotor experiences of daily living (part I of MDS-UPDRS); mMIDI = modified Minnesota Impulsive Disorders Interview; PDQ-39 SI = 39-item Parkinson's Disease Questionnaire Summary Index; UDysRS = Unified Dyskinesia Rating Scale (measured only on patients having dyskinesia, n = 50).